Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France
Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up
Doravirine works as well as efavirenz with fewer CNS side-effects
Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy
Truvada PrEP use rising in United States, especially among men
One third of TB cases in Eastern European HIV clinic survey multi-drug resistant
Australia performs best in HIV treatment cascade – 62% with undetectable viral load
Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds
Efavirenz compromises hormonal contraceptive implant
Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?
